These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 23113603

  • 1. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I, Vansteenkiste J.
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [Abstract] [Full Text] [Related]

  • 2. Chemotherapy-induced anemia: the story of darbepoetin alfa.
    Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M.
    Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 4. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.
    Vansteenkiste J, Wauters I.
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560
    [Abstract] [Full Text] [Related]

  • 5. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 6. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 7. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
    Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA.
    J Clin Oncol; 2009 Jun 10; 27(17):2838-47. PubMed ID: 19380447
    [Abstract] [Full Text] [Related]

  • 8. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct 10; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E, Demarteau N, Van Belle S, Annemans L.
    Oncologist; 2008 May 10; 13(5):596-607. PubMed ID: 18515745
    [Abstract] [Full Text] [Related]

  • 11. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 May 10; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa and history of thromboembolic events.
    Ferretti G, Felici A, Cognetti F.
    J Clin Oncol; 2009 Nov 20; 27(33):e211; author reply e212. PubMed ID: 19858373
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 20; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 16. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.
    Hess G, Hill J, Clough J, Hulnick S, Nordyke RJ.
    Curr Med Res Opin; 2008 Mar 20; 24(3):815-9. PubMed ID: 18257979
    [Abstract] [Full Text] [Related]

  • 17. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.
    Lung Cancer; 2012 Jun 20; 76(3):478-85. PubMed ID: 22277104
    [Abstract] [Full Text] [Related]

  • 18. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF.
    Cancer Treat Rev; 2006 Jun 20; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.